Detalhe da pesquisa
1.
Matrix Metalloproteases and Cathepsin D in Human Serum do not Cleave Prolactin to Generate Vasoinhibin.
Clin Lab
; 66(5)2020 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32390374
2.
TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
Br J Cancer
; 120(5): 555-564, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30765874
3.
High Prolactin Excretion in Patients with Diabetes Mellitus and Impaired Renal Function.
Clin Lab
; 61(7): 709-16, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26299069
4.
FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Eur Urol
; 83(1): 70-81, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273937
5.
Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells.
EBioMedicine
; 92: 104602, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37148583
6.
Levosulpiride Increases the Levels of Prolactin and Antiangiogenic Vasoinhibin in the Vitreous of Patients with Proliferative Diabetic Retinopathy.
Transl Vis Sci Technol
; 9(9): 27, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32879783
7.
APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Eur Urol
; 76(1): 9-13, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30975452
8.
Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study.
Nutrients
; 11(7)2019 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31319484
9.
An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.
EMBO Mol Med
; 10(4)2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29463565